The American Heart Association (AHA) has awarded Kaiser Permanente's division of research and Stanford University Medical Center $3.89 million over the next four years to establish jointly a new heart research center that aims to define optimal clinical care for patients with coronary heart disease and chronic heart failure.
The Kaiser Permanente division of research in Oakland, Calif., and Stanford Medical Center in Stanford, Calif., will conduct observational effectiveness and safety studies of therapies for the diseases by leveraging Kaiser’s clinical databases, and by using both Kaiser Permanente's division of research and Stanford scientists.
The first two studies by the new center will use analytic research methods to evaluate the effectiveness of various pharmacologic therapies and emerging technologies in patients with a variety of heart conditions. The treatments include prescription drugs, implanted devices such as stents and defibrillators, and procedures such as coronary bypass surgery.
The AHA-Pharmaceutical Roundtable (AHA-PRT) Outcomes Research Center is co-led by Mark Hlatky, MD, professor of health research and policy, and professor of medicine at Stanford, and Alan Go, MD, senior research scientist at Kaiser’s research division, and regional medical director of clinical trials. Several other of Kaiser’s research investigators are co-investigators and research mentors.